This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-22. Anything still debated is marked as such rather than presented as settled.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| 纯度检测 | RP-HPLC，214 nm | 乙腈/水梯度，含 0.1% 三氟乙酸 |
| 身份确认 | ESI-MS 或 LC-MS/MS | 比对实测与理论分子量 |
| 冻干粉储存 | -20 °C，干燥避光 | 分装可减少开盖次数 |
| 复溶液储存 | 2-8 °C，短期使用 | 避免反复冻融与长时间室温放置 |
| 主要降解途径 | 水解、氧化、脱酰胺 | 碱性 pH 与强光会加快反应 |
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Raw feeding is the practice of feeding domestic dogs, cats and other animals a diet consisting primarily of uncooked meat, edible bones, and organs. The ingredients used to formulate raw diets can vary. Some pet owners choose to make homemade raw diets to feed their animals but commercial raw food diets are also available. Frozen, or fresh-prepared, meals come in raw or cooked form, some of which is made with ingredients that are inspected, approved, and certified by the USDA for human consumption, but formulated for pets. Part of this growing trend is the commercialization of home-made dog food for pet owners who want the same quality, but do not have the time or expertise to make it themselves. The advantage is forgoing the processing stage that traditional dog food undergoes. This causes less destruction of its nutritional integrity. The practice of feeding raw diets has raised some concerns due to the risk of foodborne illnesses, zoonosis and nutritional imbalances. People who feed their dogs raw food do so for a multitude of reasons, including but not limited to: culture, beliefs surrounding health, nutrition and what is perceived to be more natural for their pets. Feeding raw food can be perceived as allowing the pet to stay in touch with their wild, carnivorous ancestry. The raw food movement has occurred in parallel to the change in human food trends for more natural and organic products.
Airport surveillance radar – In aviation, radar is the main tool of air traffic control. A rotating dish antenna sweeps a vertical fan-shaped beam of microwaves around the airspace and the radar set shows the location of aircraft as "blips" of light on a display called a radar screen. Airport radar operates at 2.7 – 2.9 GHz in the microwave S band. In large airports the radar image is displayed on multiple screens in an operations room called the TRACON (Terminal Radar Approach Control), where air traffic controllers direct the aircraft by radio to maintain safe aircraft separation. Secondary surveillance radar – Aircraft carry radar transponders, transceivers which when triggered by the incoming radar signal transmit a return microwave signal. This causes the aircraft to show up more strongly on the radar screen. The radar which triggers the transponder and receives the return beam, usually mounted on top of the primary radar dish, is called the secondary surveillance radar. Since radar cannot measure an aircraft's altitude with any accuracy, the transponder also transmits back the aircraft's altitude measured by its altimeter, and an ID number identifying the aircraft, which is displayed on the radar screen. Electronic countermeasures (ECM) – Military defensive electronic systems designed to degrade enemy radar effectiveness, or deceive it with false information, to prevent enemies from locating local forces. It often consists of powerful microwave transmitters that can mimic enemy radar signals to create false target indications on the enemy radar screens.
== Similar approaches == The idea of using protein design to accomplish the same goals as DNA origami has surfaced as well. Researchers at the National Institute of Chemistry in Slovenia are working on using rational design of protein folding to create structures much like those seen with DNA origami. The main focus of current research in protein folding design is in the drug delivery field, using antibodies attached to proteins as a way to create a targeted vehicle.
{\displaystyle \mathbf {V} (f_{n},\tau _{n})={\begin{bmatrix}cosh(\tau _{n}{\sqrt {-f_{n})}}&1/{\sqrt {-f_{n}}}sinh(\tau _{n}{\sqrt {-f_{n}}}\\{\sqrt {-f_{n}}}sinh(\tau _{n}{\sqrt {-f_{n}}})&cosh(\tau _{n}{\sqrt {-f_{n}}})\end{bmatrix}}\qquad f_{n}<0\qquad \qquad (3b)}
Valve integrated the Havok physics engine, which simulates real-world physics, to reinforce the player's sense of presence and create new gameplay. To experiment, they created a minigame, Zombie Basketball, in which players used a physics-manipulating gun to throw zombies through hoops. In mid-2000, to test the physics and non-player characters, Valve built a battle between rioting citizens and police. In late 2001, Valve began creating a showreel, hoping to demonstrate it at E3 the next year. For several months, Newell let the team work without his input so he could provide unbiased feedback, and focused on developing Steam, Valve's upcoming digital distribution service. The team presented the showreel to Newell, showcasing physics, environments such as the Borealis, and a dialogue-heavy scene with the scientist character Dr. Kleiner. Newell felt the showreel did not adequately show how the physics would affect gameplay and that the Kleiner scene was overlong. Reflecting on the feedback, Laidlaw concluded that the character drama had to support interactivity and gameplay. In September 2002, the team completed a second showreel, featuring a buggy race along the City 17 coast, an encounter with headcrabs on a pier, an alien strider attacking the city, and a greatly shortened Kleiner sequence. In October, Newell told the team they would announce Half-Life 2 at E3 2003 and release it by the end of the year. As with the original Half-Life, the team split into "cabals" working on different levels.
Sources: en.wikipedia.org
==== Morphological plasticity in the supraoptic nucleus ==== Anatomical studies using electron microscopy have shown that the morphology of the supraoptic nucleus is remarkably adaptable. For example, during lactation there are large changes in the size and shape of the oxytocin neurons, in the numbers and types of synapses that these neurons receive, and in the structural relationships between neurons and glial cells in the nucleus. These changes arise during parturition, and are thought to be important adaptations that prepare the oxytocin neurons for a sustained high demand for oxytocin. Oxytocin is essential for milk let-down in response to suckling. These studies showed that the brain is much more "plastic" in its anatomy than previously recognized, and led to great interest in the interactions between glial cells and neurons in general.
Note: For purposes of this table, genes are defined as orphan genes (when species-specific) or TRGs (when limited to a closely related group of species) when the mechanism of origination has not been investigated, and as de novo genes when de novo origination has been inferred, irrespective of method of inference. The designation of de novo genes as "candidates" or "proto-genes" reflects the language used by the authors of the respective studies.
==== Post-cancer breast reconstruction ==== After mastectomy, surgical breast reconstruction with autogenous skin flaps and with breast implants can produce subtle deformities and deficiencies resultant from such global breast augmentation, thus the breast reconstruction is incomplete. In which case, fat graft injection can provide the missing coverage and fullness, and might relax the breast capsule. The fat can be injected as either large grafts or as small grafts, as required to correct difficult axillary deficiencies, improper breast contour, visible implant edges, capsular contracture, and tissue damage consequent to radiation therapy.
== History == DESI has been widely studied since its inception in 2004 by Zoltan Takáts, Justin Wiseman and Bogdan Gologan, in Graham Cooks' group from Purdue University with the goal of looking into methods that didn't require the sample to be inside of a vacuum. Both DESI and direct analysis in real time (DART) have been largely responsible for the rapid growth in ambient ionization techniques, with a proliferation of more than eighty new techniques being found today. These methods allow for complex systems to be analyzed without preparation and throughputs as high as 45 samples a minute. DESI is a combination of popular techniques, such as, electrospray ionization and surface desorption techniques. Electrospray ionization with mass spectrometry was reported by Malcolm Dole in 1968, but John Bennett Fenn was awarded a nobel prize in chemistry for the development of ESI-MS in the late 1980s. Then in 1999, desorption of open surface and free matrix experiments were reported in the literature utilizing an experiment that was called desorption/ionization on silicon. The combination of these two advancements led to the introduction of DESI and DART as the main ambient ionization techniques that would later become multiple different techniques. One in particular, due to increasing studies into optimization of DESI, is nanospray desorption electrospray ionization (nano-DESI). In this technique the analyte is desorbed into a liquid bridge formed between two capillaries and the analysis surface.
Sources: en.wikipedia.org
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。
仅凭保留时间不足以定性，通常需要质谱给出与理论值一致的分子量。进一步可用碎裂谱与参考谱比对。保留时间、分子量与碎裂谱三者吻合时，身份判断较为可靠。
这取决于缓冲液、pH、温度与微生物负荷，并不存在通用时限。常见做法是分装冷冻并尽量缩短室温放置时间。出现浑浊或沉淀时应弃用并重新配制。
碱性 pH、较高温度、强光照射与反复冻融都会加快水解、氧化或脱酰胺。溶液中的金属离子也可能催化氧化。控制这些变量比单纯降低浓度更有效。